The Effects of Single-dose Administration of a Novel Selective alpha2c Antagonist on Emotional and Cognitive Processing in Healthy Volunteers: an fMRI Investigation
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
At a glance
- Drugs ORM 12741 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Acronyms SNAP_MRI
- 09 Jan 2019 Status changed from recruiting to completed.
- 04 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.
- 04 Oct 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.